BackMankind Pharma Limited Overview

Mankind Pharma Limited EBIT

Track Mankind Pharma Limited's EBIT ($34B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$10.34B
↑ 30.66% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$33.81B
↑ 16.74% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Mankind Pharma Limited (MANKIND.BO) FAQ

The latest EBIT for MANKIND.BO is $34B as of September 2026. That compares with $29B in the prior-year period — up 16.7% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Mankind Pharma Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, MANKIND.BO's EBIT moved from $29B to $34B — a 16.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mankind Pharma Limited's operating scale or balance-sheet position.

Against its sector companies, MANKIND.BO currently prints $34B for EBIT, while the sector average sits near $2.4T. That is roughly 98.6% below the sector mean. Large gaps often invite a closer look at Mankind Pharma Limited's growth, margins, and balance sheet.

A EBIT figure of $34B for MANKIND.BO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting MANKIND.BO's EBIT ($34B), review year-over-year change from $29B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers